Evidence map›Paper›PMID 33668509›Full record

ArticleMetabolites2021

Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma.

Marina Radoul, Donghyun Hong, Anne Marie Gillespie, Chloé Najac, Pavithra Viswanath, Russell O Pieper, Joseph F Costello, Hema Artee Luchman, Sabrina M Ronen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Energy metabolism in health and diseases.Signal transduction and targeted therapy · 2025
    Review
  4. IDH mutant high-grade gliomas.Frontiers in molecular neuroscience · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Marina RadoulDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158, USA.
Donghyun HongDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158, USA.
Anne Marie GillespieDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158, USA.
Chloé NajacDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158, USA.ORCID 0000-0002-7804-2281
Pavithra ViswanathDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158, USA.
Russell O PieperDepartment of Neurological Surgery, Helen Diller Research Center, University of California, San Francisco, CA 94158, USA.
Joseph F CostelloDepartment of Neurological Surgery, Helen Diller Research Center, University of California, San Francisco, CA 94158, USA.
Hema Artee LuchmanArnie Charbonneau Cancer Institute and Hotchkiss Brain Institute, University of Calgary, Calgary, AB T2N 4N1, Canada.
Sabrina M RonenDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94158, USA.
University of California, San Francisco · USUniversity of Calgary · CA

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7M
Metabolic Reprogramming in Brain TumorsR01CA172845 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RONEN, SABRINA MIRIAM · 2013 to 2022
$6.3M
Metabolic Imaging of Brain Tumor Response to TherapyR01CA197254 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RONEN, SABRINA MIRIAM · 2016 to 2020
$3.2M
NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA172845NCI NIH HHS R01 CA197254NIH HHS R01CA172845NIH HHS R01CA197254UCSF Loglio collective
6 · The paper itself

Abstract

Approximately 80% of low-grade glioma (LGGs) harbor mutant isocitrate dehydrogenase 1/2 (IDH1/2) driver mutations leading to accumulation of the oncometabolite 2-hydroxyglutarate (2-HG). Thus, inhibition of mutant IDH is considered a potential therapeutic target. Several mutant IDH inhibitors are currently in clinical trials, including AG-881 and BAY-1436032. However, to date, early detection of response remains a challenge. In this study we used high resolution

Indexed as

1H-MRSgliomamutant IDH inhibitornoninvasive metabolic biomarkers

Identifiers

PMID33668509
PMCPMC7917625
OpenAlexW3132541859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.